Emerald Archiving closes doors
After nearly 15 years in the PACS archive outsourcing business, Emerald Archiving is calling it quits. The company officially closed its doors in December. Emerald provided backfile image conversion services to help PACS customers make the
After nearly 15 years in the PACS archive outsourcing business, Emerald Archiving is calling it quits. The company officially closed its doors in December. Emerald provided backfile image conversion services to help PACS customers make the transition from film to DICOM and to migrate from an existing archive to a new archive. Despite having worked with two dozen hospitals across the U.S., as well as some sites in Canada and Italy, the company was never able to turn a profit and ultimately ran out of money, according to former president and CEO Joe Friedman.
"The PACS market is going forward a lot more slowly than people expected, and we didn't have the financial backing to 'stay the course,'" he said. "But I still believe this is a valid concept and there is an opportunity for someone to have a viable company."
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
